<DOC>
	<DOCNO>NCT01201278</DOCNO>
	<brief_summary>This study design compare safety tolerability two different dos intranasally administer regular human insulin single dose rapid-acting insulin analog lispro Humalog® subcutaneous injection . In addition safety tolerability , various pharmacokinetic ( PK ) pharmacodynamic ( PD ) parameter evaluate mean euglycemic glucose clamp technique .</brief_summary>
	<brief_title>PK/PD Study Intranasal Insulin Type I Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<criteria>1 . Male female subject type 1 diabetes age 18 65 year , inclusive . 2 . Type 1 diabetes clinically diagnose ≥ 12 month . 3 . Treated multiple daily insulin injection ≥ 12 month insulin pump . 4 . HbA1c ≤ 10 % local laboratory analysis ( one retest within week permit result last test conclusive ) . 5 . Fasting serum Cpeptide ≤ 0.3 nmol/L . 6 . BMI 1828 kg/m² , inclusive . 7 . Signed , write IRBapproved informed consent . 1 . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , oncologic , neurologic ( include history seizure ) disease ; hypoglycemic episode ; intercurrent illness ( influenza ) ; allergic disease ( include severe drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Clinical significance determine PI . 2 . History recent nose bleed , history nasal polyp , nasal surgery cosmetic rhinoplasty cauterization . 3 . As judged investigator , clinically significant finding laboratory data . ( Anemia hematocrit less 33 % screen specifically exclusionary . ) 4 . Clinically significant abnormal ECG screening , judge Investigator . 5 . Clinically significant abnormality vital sign screen , judge Investigator . 6 . Known allergy trial product ingredient study drug . 7 . Positive HIV 1 ( human immunodeficiency virus ) antibody test , hepatitis B ( antiHBsAg ) hepatitis C ( antiHCV ) antibody test . 8 . History evidence alcohol drug abuse within past 3 year . 9 . History deep leg vein thrombosis frequent appearance deep leg vein thrombosis 1st degree relative ( parent , sibling child ) judge Investigator . 10 . Use drug may interfere interpretation study result know cause clinically relevant interference insulin action glucose utilization . 11 . Blood donation high volume phlebotomy , e.g. , &gt; 500 mL , within 56 day dose . 12 . Participation study investigational drug device 30 day enrollment study . 13 . The subject unfit study opinion investigator . 14 . Female childbearing potential pregnant , breastfeed intend become pregnant use adequate contraceptive method ( adequate contraceptive measure include sterilization , hormonal intrauterine device , oral contraceptive , sexual abstinence vasectomize partner ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>intranasal insulin</keyword>
</DOC>